Enzymic synthesis and biological evaluation of injectable glutathione-everolimus
An enzymic synthesis of glutathione-everolimus is reported. This process has been optimized and scaled up with high reproducibility and yields, which will facilitate the development of such conjugate. The stability of the conjugate supported that this prodrug can be prepared into lyophilized solid, which is to be reconstituted with 0.9% sodium chloride for injection before intravenous infusion. And the results of species-related drug release experiment displayed that the performance of the conjugate in human plasma, rat and monkey was similar. Moreover, the in vivo efficacy of glutathione-everolimus in the treatment of renal cell carcinoma was investigated in detail. The conjugate was proved to be an effective, safe and well-tolerated injectable prodrug in the treatment of renal cell carcinoma. The results indicated that three times injection with a high dosage in 1 week can achieve much better in vivo efficacy, and no obvious toxic response was observed.
KeywordsEverolimus Glutathione Renal cell carcinoma Prodrug Drug delivery mTOR
This work was financially supported by the Key Science and Technology Innovation Team of Zhejiang Province (2013TD10).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no competing interests.
- Eble JN, Sauter G, Epstein JI, Sesterhenn IA (2004) World Health Organization classification of tumors. IARC, LyonGoogle Scholar
- Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Kay A, Ravaud A (2010) Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116:4256–4265CrossRefPubMedGoogle Scholar
- Ryan J, PA P (2013) Cyclodextrin-based polymers for therapeutics delivery. US Patent 2012-0065161. Filled 12 Aug 2011, Issued 15 Mar 2012Google Scholar
- Shirotake S, Yasumizu Y, Ito K, Masunaga A, Ito Y, Miyazaki Y, Hagiwara M, Kanao K, Mikami S, Nakagawa K, Momma T, Masuda T, Asano T, Oyama M, Tanaka N, Mizuno R, Oya M (2016) Impact of second-line targeted therapy dose intensity on patients with metastatic renal cell carcinoma. Clin Genitourin Cancer 14:e575–e583CrossRefPubMedGoogle Scholar
- Tomalova B, Sirova M, Rossmann P, Pola R, Strohalm J, Chytil P, Cerny V, Tomala J, Kabesova M, Rihova B, Ulbrich K, Etrych T, Kovar M (2016) The structure-dependent toxicity, pharmacokinetics and anti-tumor activity of HPMA copolymer conjugates in the treatment of solid tumors and leukemia. J Control Release 223:1–10CrossRefPubMedGoogle Scholar
- Weikert S, Kempkensteffen C, Busch J, Johannsen M, Grünwald V, Zimmermann K, Flörcken A, Westermann J, Weinkauf L, Miller K, Keilholz U (2013) Sequential mTOR inhibitor treatment with temsirolimus in metastatic renal cell carcinoma following failure of VEGF receptor tyrosine kinase inhibitors. World J Urol 31:805–809CrossRefPubMedGoogle Scholar
- Zhu T, Shah SM, Saunders RW (2002) Water soluble SDZ-RAD esters. EP Patent 2002-1210350. Filled 16 Aug 2000, Issued 06 May 2002Google Scholar